tbuckley/cabot-search huggingface dataset:
Brotes epidémicos Salmonella enterica serovar monofásica 4,[5],12:i:- en Luxemburgo, 2006
Authors: J Mossong, P Marques, C Ragimbeau, P Huberty-Krau, S Losch, G Meyer, G Moris, C Strottner, W Rabsch, F Schneider
Journal: Eurosurveillance (2007)

Una cepa monofasica de Salmonella enterica, la serovariante 4,[5],12:i:- tipo fago DT193, afloro como la serovariante dominante en Luxemburgo en 2006, pais en el que provoco dos brotes epidemicos importantes que causaron 133 infecciones humanas confirmadas en laboratorio, 24 hospitalizaciones y una muerte.
Efficacy and safety of everolimus and exemestane for metastatic breast cancer patients: a real-life experience of three Oncology Departments
Authors: I. Meattini, B. Salvadori, L. Coltelli, M. Perna, G.A. Carta, C. Becherini, R. Grassi, P. Garlatti, S. Cappelli, I. Desideri, A. Vannini, A. Fontana, E. Landucci, A. Michelotti, S. Ricci, G. Allegrini, A. Falcone, L. Livi
Journal: Annals of Oncology (2017)
P2.15-004 Underrepresentation of Elderly Patients with ED-SCLC as Clinical Trial Candidates (JCOG1201/TORG1528)
Authors: Y. Misumi, T. Shimokawa, H. Okamoto, S. Atagi, H. Tanaka, K. Goto, K. Nakagawa, T. Hida, N. Yamamoto, Y. Hosomi, T. Kato, I. Okamoto, Y. Ohe
Journal: Journal of Thoracic Oncology (2017)
Surveillance de la grippe en Europe d'octobre 1999 à février 2000
Authors: K Mantey, A Mosnier
Journal: Eurosurveillance (2000)

La surveillance de la grippe durant l’hiver 1999-2000 par le reseau EISS (European Influenza Surveillance Scheme) indique que la grippe a eu un impact significatif dans la plupart des 11 pays participants et qu’elle a ete particulierement active autour des mois de decembre 1999 et janvier 2000. L'activite grippale dans la population generale a ete essentiellement due aux virus A(H3N2), associes dans certains pays de la zone EISS a une situation epidemique parmi les trois plus fortes des dix dernieres annees. Huit pays - l’Allemagne, la Belgique, l’Espagne, la France, l’Italie, les Pays-Bas, la Republique Tcheque et la Suisse - ont connu une activite intense. L'absence d'une definition de cas commune reste un obstacle a la comparabilite des donnees, et l’un des axes prioritaires de developpement de EISS repose maintenant sur la standardisation des principaux indicateurs recueillis et des seuils epidemiques.
La Unión Europea se enfrenta a la amenaza de una pandemia: reunión sobre la gripe A (H5N1) en la DGV del grupo especialmente destinado a las enfermedades transmisibles, Luxemburgo, 14 de enero de 1998
Authors: J C Desenclos, R Manigat
Journal: Eurosurveillance (1998)

La transmision de un virus gripal aviar H5N1 a un nino de Hong Kong en mayo de 1997, seguida de la aparicion de otros 17 casos humanos con una alta tasa de letalidad (6/18, 33%) (1) sugirio que podria tratarse de una pandemia de gripe inminente e hizo que muchos paises europeos adoptasen medidas preventivas.
FGF23 Concentration and <i>APOL1</i> Genotype Are Novel Predictors of Mortality in African Americans With Type 2 Diabetes
Authors: Gary C. Chan, Jasmin Divers, Gregory B. Russell, Carl D. Langefeld, Lynne E. Wagenknecht, Fang-Chi Hsu, Jianzhao Xu, S. Carrie Smith, Nicholette D. Palmer, Pamela J. Hicks, Donald W. Bowden, Thomas C. Register, Lijun Ma, J. Jeffrey Carr, Barry I. Freedman
Journal: Diabetes Care (2017)

Cardiovascular and renal complications contribute to higher mortality in patients with diabetes. We assessed novel and conventional predictors of mortality in African American-Diabetes Heart Study (AA-DHS) participants.Associations between mortality and subclinical atherosclerosis, urine albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), plasma fibroblast growth factor 23 (FGF23) concentration, African ancestry proportion, and apolipoprotein L1 genotypes (APOL1) were assessed in 513 African Americans with type 2 diabetes; analyses were performed using Cox proportional hazards models.At baseline, participants were 55.6% female with median (25th, 75th percentile) age 55 years (49.0, 62.0), diabetes duration 8 years (5.0, 13.0), glycosylated hemoglobin 60.7 mmol/mol (48.6, 76.0), eGFR 91.3 mL/min/1.73 m2 (76.4, 111.3), UACR 12.5 mg/mmol (4.2, 51.2), and coronary artery calcium 28.5 mg Ca2+ (1.0, 348.6); 11.5% had two APOL1 renal-risk variants. After 6.6-year follow-up (5.8, 7.5), 54 deaths were recorded. Higher levels of coronary artery calcified plaque, carotid artery calcified plaque, albuminuria, and FGF23 were associated with higher mortality after adjustment for age, sex, and African ancestry proportion. A penalized Cox regression that included all covariates and predictors associated with mortality identified male sex (hazard ratio [HR] 4.17 [95% CI 1.96-9.09]), higher FGF23 (HR 2.10 [95% CI 1.59-2.78]), and absence of APOL1 renal-risk genotypes (HR 0.07 [95% CI 0.01-0.69]) as the strongest predictors of mortality.Accounting for conventional risk factors, higher FGF23 concentrations and APOL1 non-renal-risk genotypes associated with higher mortality in African Americans with diabetes. These data add to growing evidence supporting FGF23 association with mortality; mechanisms whereby these novel predictors impact survival remain to be determined.
Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
Authors: Timothy L. Lochmann, Konstantinos V. Floros, Mitra Naseri, Krista M. Powell, Wade Cook, Ryan J. March, Giovanna T. Stein, Patricia Greninger, Yuki Kato Maves, Laura R. Saunders, Scott J. Dylla, Carlotta Costa, Sosipatros A. Boikos, Joel D. Leverson, Andrew J. Souers, Geoffrey W. Krystal, Hisashi Harada, Cyril H. Benes, Anthony C. Faber
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Small-cell lung cancer (SCLC) is an often-fatal neuroendocrine carcinoma usually presenting as extensive disease, carrying a 3% 5-year survival. Despite notable advances in SCLC genomics, new therapies remain elusive, largely due to a lack of druggable targets. Experimental Design: We used a high-throughput drug screen to identify a venetoclax-sensitive SCLC subpopulation and validated the findings with multiple patient-derived xenografts of SCLC. Results: Our drug screen consisting of a very large collection of cell lines demonstrated that venetoclax, an FDA-approved BCL-2 inhibitor, was found to be active in a substantial fraction of SCLC cell lines. Venetoclax induced BIM-dependent apoptosis in vitro and blocked tumor growth and induced tumor regressions in mice bearing high BCL-2–expressing SCLC tumors in vivo. BCL-2 expression was a predictive biomarker for sensitivity in SCLC cell lines and was highly expressed in a subset of SCLC cell lines and tumors, suggesting that a substantial fraction of patients with SCLC could benefit from venetoclax. Mechanistically, we uncover a novel role for gene methylation that helped discriminate high BCL-2–expressing SCLCs. Conclusions: Altogether, our findings identify venetoclax as a promising new therapy for high BCL-2–expressing SCLCs. Clin Cancer Res; 24(2); 360–9. ©2017 AACR.
P2.02-014 Simultaneous Gene Profiling of Advanced NSCLC: Single-Molecule Quantification of DNA and RNA by nCounter3D™ Technology
Authors: C. Teixidó, A. Giménez-Capitán, G. Meredith, D. Martinez, A. Mashadi-Hossein, C. Hernan, P.M. Ross, A. Arcocha, P. Galván, N. Vilariño, S. Lopez-Padres, S. Rodriguez, J. Bertran-Alamillo, A. Prat, M. Molina-Vila, N. Reguart
Journal: Journal of Thoracic Oncology (2017)
RTHP-25. PATIENT OUTCOMES AND FACTORS ASSOCIATED WITH RECEIPT OF PROTON RADIATION THERAPY FOR ADULTS WITH PRIMARY GLIOMAS: ANALYSIS OF THE NATIONAL CANCER DATA BASE
Authors: Jaymin Jhaveri, En Cheng, Yuan Liu, Matthew Ferris, Mudit Chowdhary, Tiffany Morgan, Theresa Gillespie, Jeffrey J Olson, Alfredo Voloschin, Bree Eaton, Mark McDonald, Hui-Kuo Shu, Walter Curran, Kirtesh Patel
Journal: Neuro-Oncology (2017)

To investigate overall survival (OS) and clinical, socioeconomic, and geographic variables associated with the use of proton beam radiotherapy (PBT) for patients with primary gliomas. Patients ≥18 years old with World Health Organization (WHO) Grade I-IV gliomas treated with radiation therapy (RT) between 2004-2013 were identified in the National Cancer Data Base (NCDB). Patients were stratified based on WHO Grade and RT type (photon [XRT] versus PBT). Clinical variables included: age, year of diagnosis, tumor size, histology, chromosome 1p/19q loss of heterozygosity, methylation of O6-Methylguanine-Methyltransferase (MGMT), extent of surgical resection, and receipt of chemotherapy. Patient demographic variables included: race, gender, insurance status, income, education, geographic location, treatment facility location, distance to treating facility, and treatment facility type (academic vs. community). Multivariable logistic regression analysis (MVA) was performed to predict utilization of PBT over XRT. Kaplan-Meier method was implemented to calculate OS. 22,932 and 181 glioma patients were treated with XRT and PBT, respectively. On MVA, the following factors were associated with receipt of PBT (all p<0.05): WHO Grade I-II gliomas (Odds Ratio [OR] 11.29), West geographic facility location (OR 7.06), treatment at an academic program (OR 4.09), metropolitan residence (OR 2.62), surgical resection (OR 1.61), and younger age (OR 1.03). The median and 5-year OS for WHO Grade I-II glioma patients treated with PBT was not reached and 76.6%, respectively. The median and 5-year OS for WHO Grade III-IV glioma patients treated with PBT was 27.9 months and 32.3%, respectively. PBT is effective for patients with primary gliomas, although formal comparisons to outcomes of similar patients receiving XRT, is needed. Patient demographic, disease, and treatment related variables associated with the receipt of PBT should be recognized in evaluation of potential healthcare disparities in the United States and incorporated into the design of future and current clinical trials evaluating PBT.
Abstract 13490: Azosemide, a Long-acting Loop Diuretic, is Superior to Furosemide in Prevention of Cardiovascular Death in Heart Failure Patients Without Beta-blockade
Authors: Miho Fukui, Takeshi Tsujino, Shinichi Hirotani, Hiroshi Ito, Kazuhiro Yamamoto, Takashi Akasaka, Yutaka Hirano, Nobuyuki Ohte, Takashi Daimon, Satoshi Nakatani, Tohru Masuyama
Journal: Circulation (2013)

Introduction: We have previously reported that a long-acting loop diuretic, azosemide, reduces a composite of cardiovascular death or unplanned admission to hospital for congestive heart failure in...
P1.03-001 Verification and Implementation of the VENTANA Anti-ALK D5F3 Antibody in Detecting ALK Rearrangement in NSCLC
Authors: N. Nadira, H. Al-Najjar, C. Higgins, A. Wallace, J. Harris, S. Bailey, D. Shelton, S. Thiryayi, D. Rana
Journal: Journal of Thoracic Oncology (2017)
Prognostic role of aspartate aminotransferase-lymphocyte ratio index (ALRI) in patients with metastatic colorectal cancer: results from the ITACa trial
Authors: A. Passardi, E. Scarpi, M. Valgiusti, O. Nanni, G.L. Frassineti, D. Amadori, A. Casadei Gardini
Journal: Annals of Oncology (2017)
Maintenance treatment with bevacizumab in metastatic colorectal cancer: intermittent or continuous therapy? A monoinstitutional observational study
Authors: E. Cerchiaro, M. Squadroni, F. Brena, M.G. Sauta, M. Bonomi, C. Ripa, R. Barile, P. Salvini, G.L. Ceresoli, G. Beretta
Journal: Annals of Oncology (2017)
P2.01-059 Breast Metastasis from Pulmonary Cancer: A Case Report. University Hospital “Shefqet Ndroqi” Tirana Albania 2008
Authors: F. Gradica, D. Argjiri, L. Lisha, I. Avdiu, G. Cerga, A. Lala, F. Kokici, A. Cani, A. Kalenja, L. Zhegu
Journal: Journal of Thoracic Oncology (2017)
NIMG-27. GLIOBLASTOMA TUMOR SEGMENTATION USING DEEP CONVOLUTIONAL NEURAL NETWORKS
Authors: Tiffany Ting Liu, Achal Achrol, Daniel Rubin, Steven Chang
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM), the most malignant primary brain cancer, is mainly diagnosed initially based on tumor appearance on magnetic resonance (MR) images. Segmentation of GBM tumors is an important early step in image analysis to characterize tumor phenotypic features. However, manual segmentation performed by radiologists is a laborious and time-consuming process. Also, automated lesion segmentation is a challenging task due to the heterogeneous appearance of GBM. Traditional image segmentation methods may not consistently show robust performance. Recently, deep convolutional neural networks (CNNs) demonstrate great potential in image classification and recognition tasks. Here we applied a CNN architecture called U-Net that had recently been developed to segment neuronal structures in electron microscopic images and had shown good performance in segmenting lung lesions on CT images, which had not been applied to brain lesion segmentation on MR images. We trained the CNN framework to segment whole tumors on 2-dimentional MR contrast-enhanced T1 axial images. We acquired hand-drawn regions of interest (ROI) circumscribing whole GBM tumors for a total of 8280 images from 490 cases in two independent cohorts (from the Stanford University Medical Center and the Cancer Genome Atlas), with multiple tumor image slices from each case. We trained our CNN segmentation framework on 80% of the combined dataset, evaluated on 10%, and tested on the remaining 10%. After training for 20 epochs, our framework achieved a mean dice coefficient of 79% on the test set, which is comparable in performance to the published state-of-the-art brain tumor segmentation deep learning algorithm evaluated on another dataset. Further analysis needs to be performed to compare the two frameworks using the same dataset. This deep learning framework in our analysis may be extended to segmenting lower grade gliomas or other solid tumors visualized on medical images.
RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA
Authors: Sebastian Aguiar, Bram van der Gaag, Francesco Albert Bosco Cortese
Journal: Translational Neurodegeneration (2017)

Huntington's Disease (HD) is a genetically dominant trinucleotide repeat disorder resulting from CAG repeats within the Huntingtin (HTT) gene exceeding a normal range (> 36 CAGs). Symptoms of the disease manifest in middle age and include chorea, dystonia, and cognitive decline. Typical latency from diagnosis to death is 20 years. There are currently no disease-modifying therapies available to HD patients. RNAi is a potentially curative therapy for HD. A popular line of research employs siRNA or antisense oligonucleotides (ASO) to knock down mutant Huntingtin mRNA (mHTT). Unfortunately, this modality requires repeated dosing, commonly exhibit off target effects (OTEs), and exert renal and hepatic toxicity. In contrast, a single AAV-mediated short-hairpin RNA (shRNA) dose can last years with low toxicity. In addition, we highlight research indicating that shRNA elicits fewer OTEs than siRNA when tested head-to-head. Despite this promise, shRNA therapy has been held back by difficulties controlling expression (oversaturating cells with toxic levels of RNA construct). In this review, we compare RNAi modalities for HD and propose novel methods of optimizing shRNA expression and on-target fidelity.
Um surto de listeriose associado a queijo tenro no nordoeste da Suiça, 2005
Authors: J Bille, D S Blanc, H Schmid, K Boubaker, A Baumgartner, H H Siegrist, M L Tritten, R Lienhard, D Berner, R Anderau, M Treboux, J M Ducommun, R Malinverni, D Genné, P Erard, U Waespi
Journal: Eurosurveillance (2006)

Na primavera de 2005, dez casos de listeriose foram declarados numa regiao (150 000 habitantes) do nordoeste da Suica durante um periodo de oito semanas. Eram oito pacientes imunodeprimidos com bacteriemia (tres obitos) e duas mulheres gravidas que tiveram um aborto septico. Todos os casos eram devidos ao serotipo 1/2a, com um dos dois pulsotipos identificados por electroforese em campo pulsado (PFGE). As entrevistas com os pacientes revelaram rapidamente que um queijo tenro chamado “tomme”, fabricado e distribuido localmente, era a fonte alimentar implicada no surto. L. monocytogenes sv 1/2a do mesmo pulsotipo foi identificado nas amostras desse queijo, como tambem na manteiga fabricada na mesma leitaria, em quantidades de 1000-10 000 e 10-100 ufc/g, respectivamente. A interrupcao imediata da producao, a retirada do queijo do mercado e uma alerta publica, extinguiram o surto . O facto desse queijo contaminado ser distribuido numa area limitada, e a colaboracao dos medicos locais, dos microbiologos medicos e dos servicios sanitarios alimentares contribuiram ao sucesso e a rapidez da investigacao. Este pequeno surto de listeriose sublinhou a importância de um sistema de vigilância baseada nos laboratorios com um tipificacao rapida, e da colaboracao entre medicos e microbiologos.
QLIF-13. EVALUATION OF ANXIETY SYMPTOMS AMONG BRAIN TUMOR PATIENTS; ARE WE PROVIDING APPROPRIATE, EFFECTIVE CARE?
Authors: Nancy Garren, Alvina A Acquaye, Elizabeth Vera, Boris Lisa, Christine Siegel, Deric M Park, Joo-Hee Sul, Brett J Theeler, Jing Wu, Sonja Crandon, Mark Gilbert, Terri Armstrong
Journal: Neuro-Oncology (2017)

Management of brain tumor patients can be complicated as anxiety may blur the lines of an existing complex symptomatology. Failure to evaluate or treat anxiety may increase the symptom burden compromising the cancer treatment picture and quality of life; but studies examining the occurrence and impact in brain tumor patients are limited. Patients in the Neuro-Oncology Branch Natural History Study completed the GAD-7 (7-item self-report assessing anxiety symptoms rated from 0=not at all to 3=nearly every day) at enrollment. Scores were classified according to recognized cut-offs for a significant anxiety disorder (≥10) or warranting further assessment (≥5). The association of demographic and clinical variables with anxiety were evaluated using independent t-tests and chi-square tests. 124 patients participated and were primarily white(85%), male(61%), with a median age of 48 and a diagnosis of Glioblastoma(31%). The average score was 4.1(SD=4.4, median=3.0)with a range of 0-20. Significant differences in GAD-7 scores were found in patients with previous tumor recurrence scoring 1.8 points higher than patients with no recurrence(p=0.042, n=123). Thirty eight percent of patients had at least modest anxiety(score ≥5) while 11% had high anxiety (score ≥10). Patients receiving psychotropic medications (57%) were more likely to report high anxiety than those not on psychotropic medications(8%)(p=0.003). The most common psychotropic medication was an SSRI, and 42% used 2-3 agents in combination. Anxiety was common among patients with malignant brain tumors, particularly with tumor recurrence. Severe anxiety was seen in the majority of patients on psychotropic medications, suggesting that treatment was often ineffective. Given that untreated or elevated anxiety can impair the patient’s quality of life and therefore possibly compromising or altering treatment decisions, more investigation is needed to better assess, counsel and develop better therapies for this patient population.
NTOX-12. OBESITY AS A POTENTIAL ATTRIBUTE FOR VINCRISTINE INDUCED PERIPHERAL NEUROPATHY
Authors: Tammy Sajdyk, Frances Boyle, Kaitlin Foran, Yan Tong, Pankita Pandya, Ellen Smith, Richard Ho, Elizabeth Wells, Jamie Renbarger
Journal: Neuro-Oncology (2017)

Leukemia is the most common pediatric cancer (ages 0-19; 26% of pediatric cancers) with acute lymphoblastic leukemia (ALL) being the most common subtype (75%). Due to improved multidrug treatment regimens over the past 40 years, the 5-year survival rate for these children has increased from 57% to 90%. Vincristine is a core chemotherapeutic agent in the standard multidrug treatment plan. However, due to vincristine exposure, approximately 78% of these children will develop peripheral neuropathy (Vincristine-induced peripheral neuropathy: VIPN), which may be severe in some patients. The development of VIPN is characterized by progressive motor, sensory and autonomic loss of function and usually results in dose reductions of vincristine during treatment and thus an overall loss of therapeutic efficacy. Thus it is important to understand which children may be more vulnerable to developing VIPN. We hypothesized that ALL patients who were characterized as obese at time of diagnosis would develop worse neuropathy than ALL patients who were of healthy weight. Pediatric patients between the ages of two and eighteen diagnosed with pre B-cell ALL and receiving vincristine as part of their primary chemotherapy treatment plan were enrolled prior to day 8 of initiating vincristine. Neuropathy exams were performed prospectively to assess each patient’s VIPN using The Total Neuropathy Score (TNS). Weight categories were assigned to each patient based on his/her BMI percentile. An unpaired t test was done to evaluate the difference in maximum TNS-5 item score between obese and healthy patients. We found that obese pediatric ALL patients had a significantly higher maximum TNS score than pediatric ALL patients of healthy weights (p= 0.03). Future studies investigating healthy and obese ALL patients’ recovery times from VIPN are needed to assess obesity as a risk factor not only for severity of VIPN but also chronicity of this life-altering toxicity.
Prospects for combined use of oncolytic viruses and CAR T-cells
Authors: Adam Ajina, John Maher
Journal: Journal for ImmunoTherapy of Cancer (2017)

With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic option for cancer patients. In parallel, following the favourable results of several clinical trials, adoptive cell transfer using chimeric antigen receptor (CAR)-redirected T-cells is anticipated to enter routine clinical practice for the management of chemotherapy-refractory B-cell malignancies. However, CAR T-cell therapy for patients with advanced solid tumours has proved far less successful. This Review draws upon recent advances in the design of novel oncolytic viruses and CAR T-cells and provides a comprehensive overview of the synergistic potential of combination oncolytic virotherapy with CAR T-cell adoptive cell transfer for the management of solid tumours, drawing particular attention to the methods by which recombinant oncolytic viruses may augment CAR T-cell trafficking into the tumour microenvironment, mitigate or reverse local immunosuppression and enhance CAR T-cell effector function and persistence.
P3.02-096 The Interaction Between Mast Cells and Lung Cancer Cells Through Extracellular Vesicles
Authors: S. Geva, Y. Gorzalczany, L. Roisman, M. Ilouze, R. Shemesh, R. Sagi-Eisenberg, N. Peled
Journal: Journal of Thoracic Oncology (2017)
P1.02-046 Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations
Authors: C. Xu, W. Wang, W. Zhuang, Z. Huang, Z. Song, Y. Chen, W. Liu, R. Chen, Y. Guan, X. Yi, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2017)
MA 11.01 Liquid Biopsies for Monitoring BRAF Mutation (V600E) in Advanced BRAF (V600E) Non-Small Cell Lung Cancer (NSCLC)
Authors: L. Mezquita, C. Jovelet, M. Ngocamus, E. Auclin, J. Remon, E. Green, V. Plagnol, C. Morris, A. Gazzah, C. Caramella, J. Adam, L. Lacroix, L. Friboulet, J. Soria, B. Besse, D. Planchard
Journal: Journal of Thoracic Oncology (2017)
MA 17.14 Phase I Trial Evaluating MEK Inhibitor Selumetinib with Concomitant Thoracic Radiotherapy in Non-Small-Cell Lung Cancer
Authors: K. Haslett, F. Blackhall, P. Koh, L. Ashcroft, M. Asselin, C. Harris, A. Jackson, P. Manoharan, D. Mullan, D. Ryder, M. Taylor, C. Faivre-Finn
Journal: Journal of Thoracic Oncology (2017)